Today, immune checkpoint inhibitors (ICIs) represent a gold standard treatment in the first-line setting of several tumors, including non-small cell lung cancer (NSCLC) [1,2,3], BRAF wild-type (WT) melanoma [4] and metastatic renal cell carcinoma (mRCC) [5]. Here, BRAF is linked to non-small cell lung carcinoma.